Nabla vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI clinical copilot. 85K+ clinicians, 130+ organizations. 20M patient interactions/year. Raised $70M Series C. Evolving to Adaptive Agentic Platform. Founded in Paris.
About
Nabla is a Paris-based clinical AI company founded in 2018 with a mission to reduce the documentation burden that is one of the primary drivers of clinician burnout across health systems globally. The company developed an AI clinical copilot that listens to patient-physician conversations and automatically generates structured clinical notes in the background, allowing clinicians to focus entirely on the patient rather than on documentation. Nabla's core technology applies large language models fine-tuned on medical language and SOAP note structure to produce accurate, editable documentation in real time.\n\nNabla's platform serves more than 85,000 clinicians across 130-plus organizations spanning hospitals, ambulatory practices, and digital health providers. It has facilitated over 20 million patient interactions per year, making it one of the highest-volume ambient AI documentation platforms in the market. The product supports more than 45 medical specialties, with specialty-specific note templates that reflect the distinct documentation requirements of fields ranging from psychiatry to orthopedics. Nabla is evolving its platform toward an Adaptive Agentic architecture, enabling the AI to take actions beyond note-taking — such as ordering follow-ups, drafting referrals, and surfacing clinical decision support.\n\nNabla raised a $70 million Series C to fund US expansion and platform development, following strong adoption in the European market. The company competes in the ambient clinical documentation space alongside Nuance DAX, Suki, and Abridge, but differentiates through its European regulatory expertise, multi-specialty coverage, and its strategic shift toward a full agentic clinical platform. With 20 million annual patient interactions and a clear product roadmap toward autonomous clinical workflow automation, Nabla is well positioned to grow into a broader clinical AI infrastructure role.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.